Literature DB >> 16624822

Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2.

Wonkyung Oh1, Eun-Woo Lee, Young Hoon Sung, Mi-Ran Yang, Jaewang Ghim, Han-Woong Lee, Jaewhan Song.   

Abstract

The biological mechanisms for maintaining the basal level of p53 in normal cells require nuclear exclusion and cytoplasmic degradation. Here, we showed that Jab1 facilitates p53 nuclear exclusion and its subsequent degradation in coordination with Hdm2. p53 was excluded from the nucleus in the presence of Jab1; this exclusion was prevented by leptomycin B treatment. Nuclear export of p53 was accompanied by a decrease in the levels of p53, as well as of its target proteins, which include p21 and Bax. Domain analyses of Jab1 showed that the N-terminal domain, 1-110, was capable of inducing cytoplasmic translocation of p53. Furthermore, 110-191 was required to facilitate the degradation of p53. Neither of these mutants incorporated into the CSN complex, indicating that Jab1 could affect the levels of p53 independent of intact CSN complex. Conversely, Jab1 was incapable of translocating and degrading two p53 mutants, W23S and 6KR, neither of which could be modified by Hdm2. Moreover, Jab1 did not affect the cellular localization or protein levels of p53 in p53 and Hdm2 double-null mouse embryo fibroblasts. We further observed that the ablation of endogenous Jab1 by small interfering RNA prevented Hdm2-mediated p53 nuclear exclusion. Under stressed conditions, which could sequester Hdm2 in its inactive state, Jab1 did not affect p53. Our studies implicate that Jab1 is required to remove post-translationally modified p53 and provide a novel target for p53-related cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624822     DOI: 10.1074/jbc.M601857200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Gfer is a critical regulator of HSC proliferation.

Authors:  Uma Sankar; Anthony R Means
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

2.  Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization.

Authors:  Luyang Sun; Lei Shi; Feng Wang; Peiwei Huangyang; Wenzhe Si; Jie Yang; Zhi Yao; Yongfeng Shang
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

Review 3.  Revisiting the COP9 signalosome as a transcriptional regulator.

Authors:  Daniel A Chamovitz
Journal:  EMBO Rep       Date:  2009-03-20       Impact factor: 8.807

4.  MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.

Authors:  Priyadharsini Nagarajan; Kathleen L Tober; Judith A Riggenbach; Donna F Kusewitt; Amy M Lehman; Thais Sielecki; James Pruitt; Abhay R Satoskar; Tatiana M Oberyszyn
Journal:  Mol Cancer Res       Date:  2014-05-21       Impact factor: 5.852

Review 5.  Regulation of the human catalytic subunit of telomerase (hTERT).

Authors:  Michael Daniel; Gregory W Peek; Trygve O Tollefsbol
Journal:  Gene       Date:  2012-02-13       Impact factor: 3.688

6.  Suppression of Jab1 expression inhibits proliferation and promotes apoptosis of AMC-HN-8 cells.

Authors:  Pei-Hua Li; Lin Wang; Yao-Jie Pan; Miao-Miao Sang; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

7.  JAB1/CSN5 inhibits the activity of Luman/CREB3 by promoting its degradation.

Authors:  Lisa M DenBoer; Aarti Iyer; Adam R R McCluggage; Yu Li; Amanda C Martyn; Ray Lu
Journal:  Biochim Biophys Acta       Date:  2013-04-11

8.  Down-regulation of Jab1, HIF-1alpha, and VEGF by Moloney murine leukemia virus-ts1 infection: a possible cause of neurodegeneration.

Authors:  Gina F Lungu; George Stoica; Paul K Y Wong
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

9.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

10.  JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.

Authors:  Naruji Kugimiya; Arata Nishimoto; Tohru Hosoyama; Koji Ueno; Yoshihiro Takemoto; Eijiro Harada; Tadahiko Enoki; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.